Stock Scorer

Oramed Pharmaceuticals Inc. (ORMP)

Oramed Pharmaceuticals Inc. reported revenue of 0 USD for the quarter ending 31 December 2025.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q4 '25 · ending 31 December 2025 0 —
Gross Profit Q4 '25 · ending 31 December 2025 0 —
Operating Income Q2 '26 · ending 30 June 2026 -2.8M —
Net Income Q2 '26 · ending 30 June 2026 78.2M +488.2%
Cost of Revenue Q4 '25 · ending 31 December 2025 0 —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -200K —
Free Cash Flow Q2 '26 · ending 30 June 2026 -202K —
Shares Outstanding Q2 '26 · ending 30 June 2026 42.5M +3.1%
EPS Q2 '26 · ending 30 June 2026 4.12 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 2M-15.1M64M-9.2M
20232023-12-31 1.3M-15.8M5.1M-10.5M
20222022-12-31 2.7M-40.6M-36.6M-28.4M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-312M
Q4 '232023-12-310
Q3 '232023-09-300
Q2 '232023-06-30674K
Q1 '232023-03-31666K
Q4 '222022-12-31681K
Q3 '222022-09-30682K
Q2 '222022-06-30674K
Q1 '222022-03-31666K
Q4 '212021-11-30674K
Q3 '212021-09-30682K
Q3 '212021-08-31683K
Q2 '212021-06-30674K
Q2 '212021-05-31681K
Q1 '212021-03-31666K
Q1 '212021-02-28665K
Q4 '202020-11-30674K

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-3113K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-2.8M
Q1 '262026-03-31-3.7M
Q4 '252025-12-31-5.7M
Q3 '252025-09-30-2.4M
Q2 '252025-06-30-2.5M
Q1 '252025-03-31-4.5M
Q4 '242024-12-31-3.6M
Q3 '242024-09-30-3.1M
Q2 '242024-06-30-3.1M
Q1 '242024-03-31-3M
Q4 '232023-12-31-3.9M
Q3 '232023-09-30-2.9M
Q2 '232023-06-30-3.8M
Q1 '232023-03-31-5.2M
Q4 '222022-12-31-9.7M
Q3 '222022-09-30-8.2M
Q2 '222022-06-30-11.4M
Q1 '222022-03-31-11.3M
Q4 '212021-11-30-8.1M
Q3 '212021-09-30-7.5M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-3078.2M
Q1 '262026-03-3138.3M
Q4 '252025-12-3110M
Q3 '252025-09-3048.4M
Q2 '252025-06-3013.3M
Q1 '252025-03-31-7.6M
Q4 '242024-12-31-10.2M
Q3 '242024-09-30-19.6M
Q2 '242024-06-309.2M
Q1 '242024-03-311.5M
Q3 '232023-09-30-3.2M
Q2 '232023-06-30-1.2M
Q1 '232023-03-31-3.4M
Q4 '222022-12-31-8.5M
Q3 '222022-09-30-7.1M
Q2 '222022-06-30-10.5M
Q1 '222022-03-31-10.7M
Q4 '212021-11-30-8.1M
Q3 '212021-09-30-7.5M
Q3 '212021-08-31-7.6M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-312M
Q3 '192019-08-310
Q2 '192019-05-310
Q1 '192019-02-2855K
Q4 '182018-11-3035K
Q3 '182018-08-310
Q2 '182018-05-31-86K
Q3 '172017-08-310
Q2 '172017-05-310
Q1 '172017-02-280
Q4 '162016-11-30187K
Q3 '162016-08-31502K
Q2 '162016-05-31-8K
Q1 '162016-02-294K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-200K
Q1 '262026-03-31-2.9M
Q4 '252025-12-31-466K
Q3 '252025-09-30-1.6M
Q2 '252025-06-30-3.5M
Q1 '252025-03-31-3.5M
Q4 '242024-12-31-1.9M
Q3 '242024-09-30-7.1M
Q2 '242024-06-302.1M
Q1 '242024-03-31-1.5M
Q4 '232023-12-31-1.4M
Q3 '232023-09-30-694K
Q2 '232023-06-30-2.6M
Q1 '232023-03-31-5.5M
Q4 '222022-12-31-8.1M
Q3 '222022-09-30-2.2M
Q2 '222022-06-30-8.5M
Q1 '222022-03-31-9.1M
Q4 '212021-11-30-6.9M
Q3 '212021-09-30-5.5M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-202K
Q1 '262026-03-31-2.9M
Q4 '252025-12-31-468K
Q3 '252025-09-30-1.6M
Q2 '252025-06-30-3.5M
Q1 '252025-03-31-3.5M
Q4 '242024-12-31-1.9M
Q3 '242024-09-30-7.1M
Q2 '242024-06-302.1M
Q1 '242024-03-31-1.5M
Q4 '232023-12-31-1.4M
Q3 '232023-09-30-726K
Q2 '232023-06-30-2.7M
Q1 '232023-03-31-5.7M
Q4 '222022-12-31-8.4M
Q3 '222022-09-30-2.4M
Q2 '222022-06-30-8.5M
Q1 '222022-03-31-9.2M
Q3 '212021-09-30-5.6M
Q3 '212021-08-31-6.2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3042.5M
Q1 '262026-03-3142M
Q3 '252025-09-3042.8M
Q2 '252025-06-3042.6M
Q1 '252025-03-3141.2M
Q3 '242024-09-3040.9M
Q2 '242024-06-3041.6M
Q1 '242024-03-3141.6M
Q3 '232023-09-3040.4M
Q2 '232023-06-3040.2M
Q1 '232023-03-3140M
Q3 '222022-09-3039.1M
Q2 '222022-06-3038.8M
Q1 '222022-03-3138.7M
Q3 '212021-09-3034.5M
Q2 '212021-06-3030.7M
Q1 '212021-03-3128M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-304.12
Q1 '262026-03-312.59
Q4 '252025-12-311.49
Q3 '252025-09-300.99
Q2 '252025-06-30-0.62
Q1 '252025-03-31-0.71
Q4 '242024-12-31-0.48
Q3 '232023-09-30-1.85
Q2 '232023-06-30-1.59
Q1 '232023-03-31-1.29
Q4 '222022-12-31-0.94
Q1 '212021-02-280.62
Q4 '202020-11-300.66
Q3 '202020-08-310.58
Q2 '202020-05-310.59
Q1 '202020-02-290.72
Q4 '192019-11-300.72
Q3 '192019-08-310.82
Q2 '192019-05-310.87
Q1 '192019-02-280.94